LU81352A1 - Medicament constitue par un derive de cyclopentyl-addehyde et composition le renfermant - Google Patents
Medicament constitue par un derive de cyclopentyl-addehyde et composition le renfermant Download PDFInfo
- Publication number
- LU81352A1 LU81352A1 LU81352A LU81352A LU81352A1 LU 81352 A1 LU81352 A1 LU 81352A1 LU 81352 A LU81352 A LU 81352A LU 81352 A LU81352 A LU 81352A LU 81352 A1 LU81352 A1 LU 81352A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- cyclopentyl
- cis
- trans
- formula
- product
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical class O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000000443 aerosol Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 241000083821 Teucrium marum Species 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 2-formyl-3-methyl-cyclopentyl Chemical group 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002921 anti-spasmodic effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960003910 promethazine Drugs 0.000 description 4
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 240000002218 Teucrium polium Species 0.000 description 3
- 235000019041 Teucrium polium Nutrition 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000002804 anti-anaphylactic effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241001508780 Teucrium montanum Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000008784 apnea Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- MZPIHWYCJUPOFB-UHFFFAOYSA-N 2-[2-(hydroxymethyl)-3-methylcyclopentyl]propan-1-ol Chemical compound OCC(C)C1CCC(C)C1CO MZPIHWYCJUPOFB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241001072888 Teucrium Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- BORBLDJNKYHVJP-UHFFFAOYSA-N dolichodial Chemical compound CC1CCC(C(=C)C=O)C1C=O BORBLDJNKYHVJP-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/05—Alcohols containing rings other than six-membered aromatic rings
- C07C33/12—Alcohols containing rings other than six-membered aromatic rings containing five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/14—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/17—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds
- C07C29/172—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds with the obtention of a fully saturated alcohol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/27—Polyhydroxylic alcohols containing saturated rings
- C07C31/272—Monocyclic
- C07C31/274—Monocyclic with a three to five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/30—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings with a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/45—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/35—Unsaturated compounds having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7826316 | 1978-06-03 | ||
| GB7826316 | 1978-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU81352A1 true LU81352A1 (fr) | 1980-01-22 |
Family
ID=10497850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU81352A LU81352A1 (fr) | 1978-06-03 | 1979-06-01 | Medicament constitue par un derive de cyclopentyl-addehyde et composition le renfermant |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0006061B1 (it) |
| JP (1) | JPS5513269A (it) |
| AT (1) | ATE715T1 (it) |
| AU (1) | AU4760079A (it) |
| BE (1) | BE876713A (it) |
| CA (1) | CA1107761A (it) |
| CH (1) | CH639929A5 (it) |
| DE (1) | DE2962180D1 (it) |
| FR (1) | FR2427094B1 (it) |
| GB (1) | GB2022413B (it) |
| IE (1) | IE48343B1 (it) |
| IL (1) | IL57433A (it) |
| IT (1) | IT1120984B (it) |
| LU (1) | LU81352A1 (it) |
| NZ (1) | NZ190628A (it) |
| ZA (1) | ZA792678B (it) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272172A (en) * | 1990-10-09 | 1993-12-21 | Tsumura & Co. | Iridoid derivatives and the use thereof as a drug |
| CN102942605B (zh) * | 2012-11-30 | 2016-06-15 | 沈阳药科大学 | 清香藤中环烯醚萜类化合物的制备方法及其应用 |
| BR102017003318A2 (pt) * | 2017-02-17 | 2018-10-30 | Aché Laboratórios Farmacêuticos S.A. | compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas |
| MX2022010747A (es) * | 2020-04-14 | 2022-09-23 | Firmenich & Cie | Aroma de lirio de los valles. |
-
1979
- 1979-05-29 CH CH500979A patent/CH639929A5/fr not_active IP Right Cessation
- 1979-05-29 EP EP79400340A patent/EP0006061B1/fr not_active Expired
- 1979-05-29 DE DE7979400340T patent/DE2962180D1/de not_active Expired
- 1979-05-29 IL IL57433A patent/IL57433A/xx unknown
- 1979-05-29 AT AT79400340T patent/ATE715T1/de not_active IP Right Cessation
- 1979-05-30 AU AU47600/79A patent/AU4760079A/en not_active Abandoned
- 1979-05-30 ZA ZA792678A patent/ZA792678B/xx unknown
- 1979-05-30 CA CA328,873A patent/CA1107761A/en not_active Expired
- 1979-05-31 FR FR7914041A patent/FR2427094B1/fr not_active Expired
- 1979-06-01 IT IT68189/79A patent/IT1120984B/it active
- 1979-06-01 LU LU81352A patent/LU81352A1/fr unknown
- 1979-06-01 BE BE2/57846A patent/BE876713A/xx not_active IP Right Cessation
- 1979-06-01 NZ NZ190628A patent/NZ190628A/en unknown
- 1979-06-04 JP JP6980179A patent/JPS5513269A/ja active Pending
- 1979-06-04 GB GB7919435A patent/GB2022413B/en not_active Expired
- 1979-08-08 IE IE1087/79A patent/IE48343B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2022413B (en) | 1983-02-16 |
| CA1107761A (en) | 1981-08-25 |
| AU4760079A (en) | 1979-12-13 |
| BE876713A (fr) | 1979-12-03 |
| EP0006061B1 (fr) | 1982-02-24 |
| EP0006061A1 (fr) | 1979-12-12 |
| IL57433A (en) | 1982-08-31 |
| FR2427094B1 (fr) | 1986-07-25 |
| NZ190628A (en) | 1984-11-09 |
| JPS5513269A (en) | 1980-01-30 |
| IE791087L (en) | 1979-12-03 |
| IT7968189A0 (it) | 1979-06-01 |
| IL57433A0 (en) | 1979-09-30 |
| IT1120984B (it) | 1986-03-26 |
| ZA792678B (en) | 1980-08-27 |
| ATE715T1 (de) | 1982-03-15 |
| IE48343B1 (en) | 1984-12-12 |
| CH639929A5 (fr) | 1983-12-15 |
| FR2427094A1 (fr) | 1979-12-28 |
| GB2022413A (en) | 1979-12-19 |
| DE2962180D1 (en) | 1982-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0299761B1 (en) | Anti-inflammatory aryl derivatives | |
| FR2491060A1 (fr) | Esters d'acides cyclopropanes carboxyliques apparentes a l'acide pyrethrique, leur procede de preparation et leur application a la lutte contre les parasites | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| CA1125760A (fr) | Sel d'aluminium soufre, son procede de preparation et compositions cosmetiques et pharmaceutiques et pharmaceutiques le contenant | |
| EP1014927B1 (fr) | Utilisation des shogaols et des gingerols pour la preparation de compositions deodorantes | |
| EP0006061B1 (fr) | Médicament constitué par un dérivé de cyclopentyl-aldéhyde | |
| CH621325A5 (it) | ||
| FR2559771A1 (fr) | Derives de la 3-pyrrolidinopropiophenone et procede pour leur preparation | |
| EP0135510B1 (fr) | Nouveaux medicaments appartenant a la famille des derives d'halo genobenzophenone-oxime | |
| US4883813A (en) | Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones | |
| EP0351214A1 (en) | Anti-inflammatory aryl derivatives | |
| EP0001947A1 (fr) | Dérivés de l'amino-2 thiazoline, procédé de préparation et compositions pharmaceutiques les contenant | |
| JPS6320426B2 (it) | ||
| EP0210904B1 (fr) | Phényl-(3-hexaméthylèneiminopropyl)-cétone, procédé de préparation et utilisation en thérapeutique | |
| FR2484407A1 (fr) | Derives de la nonaprenylamine, leurs sels acides d'addition et composition pharmaceutique les renfermant | |
| FR2481281A1 (fr) | Derives de la nonaprenylamine, leurs sels acides d'addition et composition pharmaceutique renfermant ces produits | |
| FR2516793A1 (fr) | Nouveaux medicaments immunomodulateurs contenant un derive de trithiazolepentamethylidene-cyanine | |
| EP0063508B1 (fr) | Dérivés de 4-phénoxy-3-hydroxy-butyramidoxime, leur procédé de préparation et leur utilisation en thérapeutique | |
| FR2555583A1 (fr) | Derives du thiazole appartenant a la famille des (4-methyl-5-thiazolyl)-alcanols, procede de preparation et utilisation en therapeutique | |
| LU82448A1 (fr) | Esters de 2-(6-methoxy-2-naphtyl)-1-propanol,leur procede de preparation et leur application en therapeutique | |
| CH639072A5 (en) | 2-[ alpha -(p-Chlorophenoxy)isobutyrate] of 2,6-pyridinedimethanol and process for its preparation | |
| FR2502462A1 (fr) | Nouveaux esters d'acide cyclopropanique comportant un substituant polyhalogene, leur procede de preparation et leur application a la lutte contre les parasites | |
| FR2470111A1 (fr) | Derives de la decaprenylamine, leurs sels acides d'addition et composition pharmaceutique utilisant ces produits | |
| FR2505823A1 (fr) | Derives d'isoprenylamine et compositions pharmaceutiques renfermant ces derives | |
| CH655302A5 (fr) | Esters d'alcools aromatiques ou heteroaromatiques, leur procede et moyens de mise en oeuvre du procede, leur utilisation dans la lutte contre les ectoparasites et les compositions les renfermant. |